Results 141 to 150 of about 1,067,293 (391)

Durability of Response to B‐Cell Maturation Antigen‐Directed mRNA Cell Therapy in Myasthenia Gravis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective We report the 12‐month follow‐up outcomes from a Phase 2 clinical trial (NCT04146051) evaluating Descartes‐08, a BCMA‐directed RNA chimeric antigen receptor T‐cell (rCAR‐T) therapy for refractory generalized myasthenia gravis (MG).
Nizar Chahin, Gregory Sahagian, Marc H. Feinberg, C. Andrew Stewart, Christopher M. Jewell, Metin Kurtoglu, Miloš D. Miljković, Tuan Vu, Tahseen Mozaffar, James F. Howard Jr, the MG‐001 Study Group   +10 more
wiley   +1 more source

A Case of Myeloid Sarcoma of Intestine

The Korean Journal of Gastroenterology, 2016
Myeloid sarcoma (MS) is an extramedullary involvement of immature myeloid proliferation. An isolated MS is defined as a myeloblastic tumor when it arises without any concomitant circulating disease.
Sung Won Lim, Hang Lak Lee, Kang Nyeong Lee, Dae Won Jun, In Young Kim, Eunjin Kim, Hyein Ahn, Chan Kum Park   +7 more
doaj   +1 more source

Granulocytic myeloid-derived suppressor cells increased in early phases of primary HIV infection depending on TRAIL plasma level [PDF]

, 2017
Background It has been demonstrated that Myeloid Derived Suppressor Cells (MDSC) are expanded in HIV-1 infected individuals and correlated with disease progression.
Abbate, Isabella, Agrati, Chiara, Ammassari, Adriana, Antinori, Andrea, BILOTTA, MARIA TERESA, Bordoni, Veronica, CAPOBIANCHI, Maria Rosaria, Casetti, Rita, Cimini, Eleonora, Martini, Federico, Pinnetti, Carmela, Sacchi, Alessandra, Tumino, Nicola, Turchi, Federica   +13 more
core   +1 more source

LOXHD1 and RHOB Expression by Monocytes Predicts Progressive Systemic Sclerosis associated Interstitial Lung Disease

Arthritis Care &Research, Accepted Article.
Objective A leading cause of death among scleroderma (SSc) patients, interstitial lung disease (ILD) remains challenging to prognosticate. The discovery of biomarkers that accurately determine which patients would benefit from close monitoring and aggressive therapy would be an essential clinical tool.
Cristina M Padilla, Robert Lafyatis, Kevin F Gibson, Christina Morse, Eleanor Valenzi, Xiaoping Chen, Xiaoyun Li, Yanwu Zhao, Yongseok Park, Dana Ascherman, Jonathan Minden, Robyn Domsic, Yingze Zhang, Daniel J Kass   +13 more
wiley   +1 more source

Use of gemtuzumab ozogamycin combined with conventional chemotherapy in patients with acute myeloid leukemia [PDF]

Einstein (São Paulo), 2011
Objective: To analyze the outcome of patients treated withgemtuzumab ozogamycin combined with conventional therapy treatedat Hospital Israelita Albert Einstein.
Guilherme Fleury Perini, Fabio Pires de Souza Santos, Iracema Esteves, Claudia Mac-Donald Bley do Nascimento, Morgani Rodrigues, Reijane Alves de Assis, Ricardo Helman, Jose Mauro Kutner, Andreza Alice Feitosa Ribeiro, Nelson Hamerschlak   +9 more
doaj  

EBF1-deficient bone marrow stroma elicits persistent changes in HSC potential

, 2020
Crosstalk between mesenchymal stromal cells (MSCs) and hematopoietic stem cells (HSCs) is essential for hematopoietic homeostasis and lineage output. Here, we investigate how transcriptional changes in bone marrow (BM) MSCs result in long-lasting effects
Cauchy, P., Dereka, M., Grosschedl, R., Grün, D., Herman, J., Lupar, E., Ramamoorthy, S.   +6 more
core   +1 more source

Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia [PDF]

, 2014
Bruton's tyrosine kinase (BTK) is a cytoplasmic protein found in all hematopoietic cell lineages except for T cells. BTK mediates signalling downstream of a number of receptors.
Advani, Alam, Ashino, Baba, Bendall, Billottet, Burger, Burger, Byrd, Chang, Cordle, Dasmahapatra, David J. MacEwan, de Weers, Dos Santos, Doyle, Fiedler, Gallay, Grandage, Gu, Guzman, Hahn, Herman, Herrmann, Honda, Honigberg, Horwood, Ishii, Juliusson, Kawakami, Kim, Kojima, Kristian M. Bowles, Kvinlaug, Lyubov Zaitseva, Megan Y. Murray, Min, Mohamed, Nanri, Park, Quek, Renneville, Rushworth, Rushworth, Rushworth, Shinners, Sivina, Spiekermann, Stuart A. Rushworth, Sujobert, Tai, Tamburini, Tomasson, Tsukada, Vellenga, Venkataraman, Vetrie, Welch, Westermann, Zaitseva   +59 more
core   +1 more source

Serum soluble mediator signatures of lupus nephritis: histological features and response to treatment

Arthritis Care &Research, Accepted Article.
Objective Lupus nephritis (LN) management remains challenging, and novel noninvasive biomarkers are needed. This study quantified serum soluble mediators in the Accelerating Medicines Partnership (AMP) LN cohort to identify biomarkers of histological features and treatment response.
Andrea Fava, Catriona A. Wagner, Carla J. Guthridge, Susan Macwana, Wade DeJager, Melissa E. Munroe, Peter Izmirly, H. Michael Belmont, Betty Diamond, Anne Davidson, Paul J. Utz, Michael H Weisman, Philip M Carlucci, Maria Dall'Era, Kenneth Kalunian, Chaim Putterman, Jennifer Anolik, Jennifer L Barnas, David Wofsy, Diane Kamen, Richard A Furie, Deepak A Rao, the Accelerating Medicines Partnership (AMP) RA/SLE Network, Michelle Petri, Joel M. Guthridge, Jill Buyon, Judith A. James   +26 more
wiley   +1 more source

Large Scale Internet-based Survey of Patients With a Myeloproliferative Neoplasm: Opinions and Experiences Regarding SARS-CoV-2 (COVID-19) Vaccination Strategies in 2021

HemaSphere, 2021
Jamie Saunders, Natalia Curto-Garcia, Priya Sriskandarajah, Jennifer O’Sullivan, Claire Woodley, Susan Asirvatham, Marion Campbell-Drew, Jonathan Mathias, Tim Ellis, Nona Baker, Deepti H. Radia, Sahra Ali, Shahram Kordasti, Patrick Harrington, Hugues de Lavallade, Donal P. McLornan, Claire N. Harrison   +16 more
doaj   +1 more source

Adipose Mesenchymal Stem Cell‐Derived Exosomes in Conjunction with Roflumilast Ameliorate Chronic Kidney Disease Through the Modulation of Fibrosis and Inflammation

Advanced Biology, EarlyView.
The novelty of this study showed that the injection of exosomes produced from ADMSCs in combination with Roflumilast poses a more favorable therapeutic outcome for CKD induced by Adriamycin, compared to therapy with exosomes or Roflumilast alone. Roflumilast and exosomes treatment lowered the expression of the apoptotic, fibrotic, and inflammatory ...
Mohamed Ali, Mohamed H. Sherif, Nashwa Barakat, Bassant Yahia, Ahmed A. Shokeir, Basel Sitohy   +5 more
wiley   +1 more source